A Case For Transparency: J&J Suit Targets Opaque PBM Affiliate’s Efforts To Exploit Copay Programs
Lawsuit highlights the lack of transparency into pharmacy benefit manager activities and how their programs can influence drug pricing. A Senate hearing on PBMs held shows increasing momentum behind a Federal Trade Commission study on potential anti-competitive activity in the market sector.
You may also be interested in...
Drug Channels’ Adam Fein described the ongoing and escalating battle between manufacturers and payers over the cost of specialty drugs during a recent webinar.
Janssen continues to pursue aggressive policies to reduce inappropriate use of 340B discounts. Firm estimates that 58% of list prices went to commercial and government insurers, 340B providers and others in the US health care system in the form of price concessions last year.
Patient groups ‘left with no choice’ but to challenge federal regulation allowing commercial payers to bar manufacturer assistance with drug costs from being counted toward deductibles and out-of-pocket spending caps.